is ketamine a bronchodilator
Reading File
Searching the Web
ketamine bronchodilator mechanism bronchospasm
Finding Sources
Yes, ketamine is a bronchodilator. Here is a full breakdown from authoritative textbooks and current evidence:
Ketamine as a Bronchodilator
Mechanism of Action
Ketamine causes bronchodilation through several mechanisms:
- Sympathomimetic / catecholamine release - the primary mechanism. Ketamine inhibits catecholamine reuptake and stimulates release, leading to beta-2 adrenergic receptor activation and bronchial smooth muscle relaxation.
- Direct smooth muscle relaxation - ketamine relaxes bronchial smooth muscle independent of its adrenergic effects (Tintinalli's EM).
- Voltage-sensitive calcium channel blockade - interrupts calcium influx into smooth muscle cells.
- Muscarinic/nicotinic receptor inhibition - blocks postsynaptic muscarinic and nicotinic receptors.
- Nitric oxide downregulation - reduces inducible nitric oxide synthase (iNOS) activity, lowering NO levels that contribute to bronchospasm.
- Anti-inflammatory effects - interrupts the inflammatory cascade that drives airway hyperreactivity.
Notably, the NMDA receptor (ketamine's classic target) does NOT appear to be the main driver of its bronchodilatory effect - research by Sato et al. (1998) showed NMDA agonists failed to block ketamine-induced smooth muscle relaxation.
Stereoisomers: Racemic vs. S(+)
An important nuance from Morgan & Mikhail (7e):
"Racemic ketamine is a potent bronchodilator... however, S(+) ketamine produces minimal bronchodilation."
This means the commonly used S-ketamine (esketamine) used in Europe may have less bronchodilatory benefit than the racemic mixture used in the US.
Clinical Applications
| Setting | Role |
|---|---|
| Asthmatic patients requiring RSI | Drug of choice for induction - sympathomimetic + bronchodilatory effects |
| Status asthmaticus | Secondary/adjunct agent when beta-2 agonists, anticholinergics, corticosteroids, and IV magnesium fail |
| Hemodynamically unstable asthmatic | Ideal - provides both cardiovascular support and bronchodilation |
| Mechanically ventilated asthmatics | Reduces airway resistance and improves pulmonary compliance |
Important Caveats
- Not a sole bronchodilator - Barash (9e) notes it is "not effective as a sole agent for the treatment of bronchospasm" and should be a secondary agent.
- Rosen's EM notes that while studies suggest possible benefit in acute asthma, no statistically significant findings have been confirmed, and "ketamine is not recommended for acute [asthma]" as a primary treatment outside of RSI.
- Increases salivation (consider pre-treatment with an antisialogogue like glycopyrrolate).
- Preserves airway reflexes and spontaneous ventilation - an advantage over other induction agents.
Dosing for Bronchospasm (from literature)
- Bolus: 0.1-2 mg/kg IV
- Continuous infusion: 0.15-2.5 mg/kg/hr
- Nebulized ketamine has also been studied in status asthmaticus
Bottom line: Yes, ketamine is a clinically meaningful bronchodilator - it's the preferred induction agent in asthmatic patients and a recognized adjunct in refractory status asthmaticus, with the Frontiers in Pediatrics case report and a comprehensive review in PMC supporting its use in bronchospasm unresponsive to conventional treatment.
This is a shared conversation. Sign in to Orris to start your own chat.